PDL BioPharma is reinventing itself as a healthcare-focused finance company through a two-pronged strategy, investing in royalty streams and providing high-yield financing life science companies with near-term product launches. This strategy allows investors to gain exposure in healthcare through a relatively low-risk, diversified vehicle. We currently value PDL at $6.84 per basic share.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Low-risk, diversified healthcare play
- Published:
21 Jul 2015 - Author:
- Pages:
PDL BioPharma is reinventing itself as a healthcare-focused finance company through a two-pronged strategy, investing in royalty streams and providing high-yield financing life science companies with near-term product launches. This strategy allows investors to gain exposure in healthcare through a relatively low-risk, diversified vehicle. We currently value PDL at $6.84 per basic share.